美国急性早幼粒细胞白血病患者的实践模式与真实世界结局
基于Vizient临床数据库分析2017年4月至2020年3月新诊断急性早幼粒细胞白血病(APL)患者1464例,14.0%发生不良结局(院内死亡或出院转临终关怀),20.6%未接受指南一致性方案,未接受指南一致性治疗、高危疾病及年龄≥60岁与不良结局风险升高相关。
要点
- 1464例新诊断APL患者中14.0%发生院内死亡或出院转临终关怀。
- 20.6%患者未接受与NCCN指南一致的方案,其不良结局OR为2.31。
- 高危疾病(OR 2.48)和年龄≥60岁(OR 11.13)与不良结局风险升高相关。
核心结论
- 在这项大型数据库分析中,14.0%的新诊断APL患者死亡或出院转临终关怀,相当比例患者未接受指南一致性治疗,可能促成不良结局。
研究设计与样本
- 使用Vizient临床数据库,描述2017年4月至2020年3月研究期间新诊断APL患者的人口学特征、基线临床特征和治疗模式。
- 共纳入1464例新诊断APL患者,以基线白细胞计数进行风险分层并评估与NCCN指南的治疗一致性。
- 采用逻辑回归模型分析患者、医院、疾病特征与不良结局(院内死亡或出院转临终关怀)之间的校正关联。
主要发现
- 1464例APL患者中205例(14.0%)发生不良结局。
- 20.6%的患者未接受指南一致性方案。
- 未接受指南一致性治疗者不良结局OR为2.31(95%CI 1.43-3.75;P=0.001)。
- 高危疾病者不良结局OR为2.48(95%CI 1.53-4.00;P<0.001);年龄≥60岁者OR为11.13(95%CI 4.55-27.22;P<0.001)。
- 医院AML患者量较高与不良结局风险降低相关(每年≤50例 vs >200例:OR 0.44;95%CI 0.20-0.99;P=0.046)。
关键数值与推荐
- 以基线白细胞计数进行风险分层并判定与NCCN指南的治疗一致性。
- 不良结局定义为院内死亡或出院转临终关怀。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute promyelocytic leukemia (APL) is associated with a favorable long-term prognosis if appropriate treatment is initiated promptly. Outcomes in clinical trials and population-based registries vary; potential explanations include a delay in treatment and lower adherence to guideline-recommended therapy in real-world practice. We used the Vizient Clinical Data Base to describe demographic characteristics, baseline clinical characteristics, and treatment patterns in patients newly diagnosed with APL during the study period of April 2017 to March 2020. Baseline white blood cell count was used to assign risk status and assess treatment concordance with National Comprehensive Cancer Network guidelines. Logistic regression models examined adjusted associations between patient, hospital, disease characteristics, and adverse outcomes (in-hospital death or discharge to hospice). Among 1464 patients with APL, 205 (14.0%) experienced an adverse outcome. A substantial subset (20.6%) of patients did not receive guideline-concordant regimens. Odds of adverse outcomes increased with failure to receive guideline-concordant treatment (odds ratio [OR], 2.31; 95% confidence interval [CI], 1.43-3.75; P = .001), high-risk disease (OR, 2.48; 95% CI, 1.53-4.00; P < .001), and increasing age (≥60 years: OR, 11.13; 95% CI, 4.55-27.22; P < .001). Higher hospital acute myeloid leukemia (AML) patient volume was associated with lower odds of adverse outcome (OR, 0.44; 95% CI, 0.20-0.99 [for ≤50 vs >200 AML patients per year]; P = .046). In conclusion, in this large database analysis, 14.0% of patients newly diagnosed with APL died or were discharged to hospice. A substantial proportion of patients did not receive guideline-concordant therapy, potentially contributing to adverse outcomes.
引用
- Bewersdorf JP, Prozora S, Podoltsev NA, et al. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Adv. 2022. PMID: 34724703. doi:10.1182/bloodadvances.2021005642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。